Laila C Roisman

List of Publications by Year
in descending order

53 papers	2,147 citations	471509 17 h-index	265206 42 g-index
53 all docs	53 docs citations	53 times ranked	3505 citing authors

#	Article	IF	Citations
1	Safety of the BNT162b2 mRNA COVID-19 vaccine in oncologic patients undergoing numerous cancer treatment options. Medicine (United States), 2022, 101, e28561.	1.0	15
2	Next-Generation Sequencing Liquid Biopsy-Guided Osimertinib Rechallenge in EGFR-Mutated Advanced Non-Small-Cell Lung Cancer Patients. Clinical Drug Investigation, 2022, 42, 185-192.	2.2	7
3	Osimertinib in advanced EGFR-mutant lung adenocarcinoma with asymptomatic brain metastases: an open-label, 3-arm, phase II pilot study. Neuro-Oncology Advances, 2022, 4, vdab188.	0.7	9
4	The impact of osimertinibâ€™ line on clonal evolution in EGFRm NSCLC through NGS-based liquid biopsy and overcoming strategies for resistance. Lung Cancer, 2021, 153, 126-133.	2.0	16
5	Epithelioid Hemangioendothelioma and Epithelioid Hemangioma: Pazopanib as a Potential Salvage Therapy. Case Reports in Oncology, 2021, 14, 309-317.	0.7	3
6	Rapid Response to the Combination of Lenvatinib and Pembrolizumab in Patients with Advanced Carcinomas (Lung Adenocarcinoma and Malignant Pleural Mesothelioma). Cancers, 2021, 13, 3630.	3.7	8
7	Genomic profiling of solid tumors harboring BRD4-NUT and response to immune checkpoint inhibitors. Translational Oncology, 2021, 14, 101184.	3.7	13
8	Dose escalation of osimertinib for intracranial progression in EGFR mutated non-small-cell lung cancer with brain metastases. Neuro-Oncology Advances, 2020, 2, vdaa125.	0.7	12
9	GLASS: Global Lorlatinib for ALK(+) and ROS1(+) retrospective Study: real world data of 123 NSCLC patients. Lung Cancer, 2020, 148, 48-54.	2.0	18
10	Programmed death-ligand 1 expression discrepancy between primary tumor and metastatic lymph nodes in non-small cell lung cancer. Journal of Thoracic Disease, 2020, 12, 3918-3920.	1.4	1
11	Non-small cell lung cancer PDL1 >50%â€”should we go single or combo?. Precision Cancer Medicine, 2020, 3, 7-7.	1.8	1
12	Nivolumab Induced Hepatocanalicular Cholestasis and Liver Rejection in a Patient With Lung Cancer and Liver Transplant. Journal of Thoracic Oncology, 2020, 15, e149-e150.	1.1	8
13	Vismodegib as First-Line Treatment of Mutated Sonic Hedgehog Pathway in Adult Medulloblastoma. JCO Precision Oncology, 2020, 4, 437-441.	3.0	4
14	Hypercalcemia as a Rebound Phenomenon of LOXO-292 Efficacy in Medullary Thyroid Cancer. JTO Clinical and Research Reports, 2020, 1, 100002.	1.1	1
15	Lung Cancer in Young Patients: Higher Rate of Driver Mutations and Brain Involvement, but Better Survival. Journal of Global Oncology, 2019, 5, 1-8.	0.5	21
16	Efficacy and Safety of BRAF Inhibitors With or Without MEK Inhibitors in BRAF-Mutant Advanced Nonâ€“Small-Cell Lung Cancer: Findings From a Real-Life Cohort. Clinical Lung Cancer, 2019, 20, 278-286.e1.	2.6	10
17	EP1.12-01 Does PCI Still Have a Role in Limited SCLC?. Journal of Thoracic Oncology, 2019, 14, S1016.	1.1	0
18	P1.04-47 Tumor Mutation Burden Through Hybrid Capture â€“ Circulating Tumor DNA May Predict Response to Immunotherapy in NSCLC. Journal of Thoracic Oncology, 2019, 14, S459.	1.1	1

#	Article	IF	Citations
19	The crystal structure of amyloid precursorâ€like protein 2 E2 domain completes the amyloid precursor protein family. FASEB Journal, 2019, 33, 5076-5081.	0.5	7
20	Amyloid Precursor Protein Dimerisation Reduces Neurite Outgrowth. Molecular Neurobiology, 2019, 56, 13-28.	4.0	8
21	Are we facing a cure in lung cancer?â€"KEYNOTE-001 insights. Annals of Translational Medicine, 2019, 7, S215-S215.	1.7	7
22	Effectiveness and safety of nivolumab in advanced non-small cell lung cancer: The real-life data. Lung Cancer, 2018, 126, 217-223.	2.0	89
23	BRAF Mutant Lung Cancer: Programmed Death Ligand 1 Expression, Tumor Mutational Burden, Microsatellite Instability Status, and Response to Immune Check-Point Inhibitors. Journal of Thoracic Oncology, 2018, 13, 1128-1137.	1.1	160
24	P3.03-15 Lung Cancer Regulation of Glucose Metabolic Stress Response. Journal of Thoracic Oncology, 2018, 13, S916.	1.1	0
25	P1.13-33 Ex Vivo 2*2*2 Tumor Tissue Explant Culture for Precision Medicine in Immunotherapy and TKI progressors in Lung Cancer. Journal of Thoracic Oncology, 2018, 13, S595.	1.1	0
26	P3.04-11 The Influence of Circulating Tumor DNA Analysis on Response to Immunotherapy in Non-Small Cell Lung Cancer (NSCLC). Journal of Thoracic Oncology, 2018, 13, S925-S926.	1.1	0
27	Two are better than one on progression through MET mechanism for EGFR+ NSCLC patients. Translational Lung Cancer Research, 2018, 7, S334-S335.	2.8	3
28	P2.01-02 Osimertinib for EGFR-Positive Advanced NSCLC with Brain Metastases: Preliminary Analysis of an Open-Label, Two-Arm, Phase 2 Study. Journal of Thoracic Oncology, 2018, 13, S665-S666.	1.1	1
29	MA06.05 The Micro-Environmental Cross Talk Between Mast Cells and Lung Cancer Cells Through Cell-to-Cell Contact. Journal of Thoracic Oncology, 2018, 13, S376.	1.1	1
30	The Clinical Impact of Comprehensive Genomic Testing of Circulating Cell-Free DNA in Advanced Lung Cancer. Journal of Thoracic Oncology, 2018, 13, 1705-1716.	1.1	38
31	146P The clinical impact of comprehensive cfDNA genomic testing in lung cancer. Journal of Thoracic Oncology, 2018, 13, S87.	1.1	0
32	145P Impact of next-generation sequencing on survival in lung cancer. Journal of Thoracic Oncology, 2018, 13, S86-S87.	1.1	2
33	Rare targetable drivers (RTDs) in non-small cell lung cancer (NSCLC): Outcomes with immune check-point inhibitors (ICPi). Lung Cancer, 2018, 124, 117-124.	2.0	46
34	Rare targetable drivers (RTD) in NSCLC: PD-L1 expression, tumor mutation burden (TMB), microsatellite instability (MSI) and outcomes with immune check-point inhibitors (ICPi).. Journal of Clinical Oncology, 2018, 36, 9076-9076.	1.6	0
35	Subclonal Therapy by Two EGFR TKIs Guided by Sequential Plasma Cell-free DNA in EGFR -Mutated Lung Cancer. Journal of Thoracic Oncology, 2017, 12, e81-e84.	1.1	41
36	Tau-mediated iron export prevents ferroptotic damage after ischemic stroke. Molecular Psychiatry, 2017, 22, 1520-1530.	7.9	449

#	Article	IF	Citations
37	P3.01-060 The Clinical Utility of ctDNA Gene Analysis in Lung Cancer. Journal of Thoracic Oncology, 2017, 12, S2224-S2225.	1.1	0
38	P3.02-096 The Interaction Between Mast Cells and Lung Cancer Cells Through Extracellular Vesicles. Journal of Thoracic Oncology, 2017, 12, S2272.	1.1	0
39	MA 02.06 BRAF Mutant NSCLC: Correlation with PD-L1 Expression,TMB, MSI and Response to ICPi and Anti-BRAF Therapy. Journal of Thoracic Oncology, 2017, 12, S1804-S1805.	1.1	7
40	Abstract 5394: The clinical impact of multiplex ctDNA gene analysis in lung cancer. , 2017, , .		0
41	Abstract LB-041: Novel platform to profile variants of uncertain significant (VUS) with preliminary retrospective clinical validation in non-small cell lung cancer (NSCLC). , 2017, , .		0
42	Liquid biopsy in the practice of neo-oncology. Journal of Thoracic Disease, 2016, 8, E1279-E1281.	1.4	2
43	The neuroprotective activity of the amyloid precursor protein against traumatic brain injury is mediated via the heparin binding site in residues 96â€110. Journal of Neurochemistry, 2014, 128, 196-204.	3.9	46
44	Interferon-Îµ Protects the Female Reproductive Tract from Viral and Bacterial Infection. Science, 2013, 339, 1088-1092.	12.6	197
45	N-Methylpurine DNA Glycosylase and OGG1 DNA Repair Activities: Opposite Associations With Lung Cancer Risk. Journal of the National Cancer Institute, 2012, 104, 1765-1769.	6.3	53
46	A Molecular Basis for NKT Cell Recognition of CD1d-Self-Antigen. Immunity, 2011, 34, 315-326.	14.3	118
47	DNA repair of oxidative DNA damage in human carcinogenesis: Potential application for cancer risk assessment and prevention. Cancer Letters, 2008, 266, 60-72.	7.2	179
48	Inquiring into the Differential Action of Interferons (IFNs): an IFN-Î±2 Mutant with Enhanced Affinity to IFNAR1 Is Functionally Similar to IFN-Î². Molecular and Cellular Biology, 2006, 26, 1888-1897.	2.3	217
49	Mutational Analysis of the IFNAR1 Binding Site on IFNÎ±2 Reveals the Architecture of a Weak Ligandâ€“Receptor Binding-site. Journal of Molecular Biology, 2005, 353, 271-281.	4.2	80
50	Optimizing the Binding Affinity of a Carrier Protein. Journal of Biological Chemistry, 2004, 279, 18046-18053.	3.4	19
51	Structure of the interferon-receptor complex determined by distance constraints from double-mutant cycles and flexible docking. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 13231-13236.	7.1	87
52	New Structural and Functional Aspects of the Type I Interferon-Receptor Interaction Revealed by Comprehensive Mutational Analysis of the Binding Interface. Journal of Biological Chemistry, 2000, 275, 40425-40433.	3.4	137
53	Liquid First Is â€œSolidâ€•in NaÃ¯ve Non-Small Cell Lung Cancer Patients: Faster Turnaround Time With High Concordance to Solid Next-Generation Sequencing. Frontiers in Oncology, 0, 12, .	2.8	5